GlaxoSmithKline is paying $176m for a 10% stake in the RNA drug developer in connection with a strategic partnership agreement.

The Roche and GSK-backed autoimmune disease drug developer has gone public in an upsized initial public offering after at least $138m in earlier funding.

Alphabet and EmblemHealth returned to help supply $53.5m for the community-focused care provider, bringing its overall funding to nearly $140m.

Adimab's coronavirus antibody spinoff has launched with series A financing from investors including GV as it prepares for its first clinical trials.

Existing investor Bioventus has returned to reinvest in the bone implant provider, whose existing backers include Johnson & Johnson Innovation – JJDC.

VC firm Artis Ventures led a round for robotic surgery software developer Activ 10 months after its Sony-backed series A funding.

Each Friday the Global Corporate Venturing Deal Net rounds up the week’s smaller deals and tracks the emerging companies accessing corporate funds.

The medical technology provider has formed Ascendum Capital Partners in partnership with DCP Capital and Qiming Venture Partners.

The Fosun and Hidea-backed stroke therapy technology developer has raised an eight-digit sum that will help advance its product pipeline.

Merck & Co backed a $14m series B for SAB Biotherapeutics, which is developing drugs for two forms of coronavirus including Covid-19.